journal
MENU ▼
Read by QxMD icon Read
search

Clinical Sarcoma Research

journal
https://www.readbyqxmd.com/read/28228934/osteosarcoma-follow-up-chest-x-ray-or-computed-tomography
#1
Anna Paioli, Michele Rocca, Luca Cevolani, Eugenio Rimondi, Daniel Vanel, Emanuela Palmerini, Marilena Cesari, Alessandra Longhi, Abate Massimo Eraldo, Emanuela Marchesi, Piero Picci, Stefano Ferrari
BACKGROUND: In patients with relapsed osteosarcoma, the surgical excision of all metastases, defined as second complete remission (CR-2), is the factor that mainly influences post-relapse survival (PRS). Currently a validated follow-up policy for osteosarcoma is not available, both chest X-ray and computed tomography (CT) are suggested for lung surveillance. The purpose of this study is to evaluate whether the type of imaging technique used for chest surveillance, chest X-ray or CT, influenced the rate of CR-2 and prognosis in patients with recurrent osteosarcoma...
2017: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/28163887/central-venous-access-related-adverse-events-after-trabectedin-infusions-in-soft-tissue-sarcoma-patients-experience-and-management-in-a-nationwide-multi-center-study
#2
Michiel C Verboom, Jan Ouwerkerk, Neeltje Steeghs, Jacob Lutjeboer, J Martijn Kerst, Winette T A van der Graaf, Anna K L Reyners, Stefan Sleijfer, Hans Gelderblom
BACKGROUND: Trabectedin has shown efficacy against soft tissue sarcomas (STS) and has manageable toxicity. Trabectedin is administered through central venous access devices (VAD), such as subcutaneous ports with tunneled catheters, Hickman catheters and PICC lines. Venous access related adverse events are common, but have not yet been reported in detail. METHODS: A retrospective analysis of patient files of STS patients receiving trabectedin monotherapy between 1999 and 2014 was performed in all five STS referral centers in the Netherlands...
2017: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/28078078/radiotherapy-in-the-management-of-gist-state-of-the-art-and-new-potential-scenarios
#3
L Gatto, M Nannini, M Saponara, V Di Scioscio, G Beltramo, G P Frezza, G Ercolani, A D Pinna, A Astolfi, M Urbini, G Brandi, G Biasco, M A Pantaleo
BACKGROUND: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. The main treatment for localized gastrointestinal stromal tumors is surgical resection. Unresectable or advanced GIST are poorly responsive to conventional cytotoxic chemotherapy but the introduction of tyrosine kinase inhibitors (TKIs) marked a revolutionary step in the treatment of these patients, radically improving prognosis and clinical benefit. Historically GIST has been considered radiation-resistant, and the role of radiotherapy in the management of patients with GIST is currently restricted to symptomatic palliation in current treatment guidelines...
2017: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/28042471/response-to-anti-pd1-therapy-with-nivolumab-in-metastatic-sarcomas
#4
L Paoluzzi, A Cacavio, M Ghesani, A Karambelkar, A Rapkiewicz, J Weber, G Rosen
BACKGROUND: Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted antibodies has recently emerged as an effective anticancer strategy in multiple malignancies. Sarcomas are a heterogeneous group of diseases in need of more effective treatments. Different subtypes of soft tissue and bone sarcomas have been shown to express PD-1 ligand. METHODS: We retrospectively analyzed a cohort of patients (pts) with relapsed metastatic/unresectable sarcomas, who were treated with nivolumab provided under a patient assistance program from the manufacturer...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/28042470/metastatic-meningioma-presenting-as-a-malignant-soft-tissue-tumour
#5
Catherine McCarthy, Monika Hofer, Marianna Vlychou, Robar Khundkar, Paul Critchley, Simon Cudlip, Olaf Ansorge, Nick A Athanasou
BACKGROUND: Extracranial metastasis of malignant meningioma to soft tissues is extremely rare and its clinical, radiological and pathological features are not well-characterised. CASE PRESENTATION: We report a case of a 58 year old man who presented with a mobile mass within the left trapezius muscle. The patient had previously undergone surgery for a right frontal lobe high grade anaplastic meningioma. Histology of the soft tissue lesion showed metastatic anaplastic meningioma with clumps of pleomorphic tumour cells which expressed epithelial membrane antigen, cytokeratin and P63 but were negative for other epithelial and mesenchymal markers...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27999655/clinical-implications-of-repeated-drug-monitoring-of-imatinib-in-patients-with-metastatic-gastrointestinal-stromal-tumour
#6
Ivar Hompland, Øyvind Sverre Bruland, Kumari Ubhayasekhera, Jonas Bergquist, Kjetil Boye
BACKGROUND: Imatinib mesylate (IM) is the preferred treatment for the majority of patients with metastatic gastrointestinal stromal tumour (GIST). Low trough IM concentration (Cmin) values have been associated with poor clinical outcomes in GIST patients. However, there are few studies of repeated measurements of IM levels, and therapeutic drug monitoring is not yet a part of routine clinical practice. This study was conducted to reveal clinical scenarios where plasma concentration measurement of IM trough level (Cmin) is advantageous...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27957320/pazopanib-a-novel-treatment-option-for-aggressive-fibromatosis
#7
Gulcan Bulut, Anil Ozluk, Atike Pınar Erdogan, Ruchan Uslu, Nevra Elmas, Burcak Karaca
BACKGROUND: Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies. CASE PRESENTATION: We present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazopanib, with mild side effects...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27891213/uk-guidelines-for-the-management-of-soft-tissue-sarcomas
#8
REVIEW
Adam Dangoor, Beatrice Seddon, Craig Gerrand, Robert Grimer, Jeremy Whelan, Ian Judson
Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues, and can occur almost anywhere in the body. Their rarity, and the heterogeneity of subtype and location means that developing evidence-based guidelines is complicated by the limitations of the data available. However, this makes it more important that STS are managed by teams, expert in such cases, to ensure consistent and optimal treatment, as well as recruitment to clinical trials, and the ongoing accumulation of further data and knowledge...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27822356/efficacy-of-pazopanib-and-sunitinib-in-advanced-axial-chordoma-a-single-reference-centre-case-series
#9
Astrid Lipplaa, Sander Dijkstra, Hans Gelderblom
BACKGROUND: Chordomas are rare malignant tumours of the axial skeleton and skull base supposed to arise from cellular remnants of the notochord. These tumours have the potential to metastasize (30-40 %), usually in the later course of the disease. However, the greatest morbidity is usually a result of loco-regional recurrence with infiltration and destruction of surrounding bone and soft tissue. Patients with unresectable or metastatic chordoma are faced with a poor prognosis since cytotoxic chemotherapy or other systemic therapies have not proven their efficacy yet...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27777717/outcome-and-the-effect-of-age-and-socioeconomic-status-in-1318-patients-with-synovial-sarcoma-in-the-english-national-cancer-registry-1985-2009
#10
Bernadette Brennan, Charles Stiller, Robert Grimer, Nicola Dennis, John Broggio, Matthew Francis
BACKGROUND: The role of age as a prognostic factor has been examined in single institutional studies and in larger data sets from the SEER database, showing a survival advantage for younger versus adult patients with synovial sarcoma (SS). To further assess the role of age, socioeconomic status and other prognostic factors on outcome for SS, we analysed a contemporary all-age population-based cohort of patients with SS registered in England. METHODS: The data on 1318 synovial sarcomas diagnosed in England between 1985 and 2009 were retrospectively analysed for incidence, and the effect of age, patient characteristics and deprivation on outcome using both univariate and multivariate analysis...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27733900/high-nuclear-expression-of-proteasome-activator-complex-subunit-1-predicts-poor-survival-in-soft-tissue-leiomyosarcomas
#11
Sha Lou, Arjen H G Cleven, Benjamin Balluff, Marieke de Graaff, Marie Kostine, Inge Briaire-de Bruijn, Liam A McDonnell, Judith V M G Bovée
BACKGROUND: Previous studies on high grade sarcomas using mass spectrometry imaging showed proteasome activator complex subunit 1 (PSME1) to be associated with poor survival in soft tissue sarcoma patients. PSME1 is involved in immunoproteasome assembly for generating tumor antigens presented by MHC class I molecules. In this study, we aimed to validate PSME1 as a prognostic biomarker in an independent and larger series of soft tissue sarcomas by immunohistochemistry. METHODS: Tissue microarrays containing leiomyosarcomas (n = 34), myxofibrosarcomas (n = 14), undifferentiated pleomorphic sarcomas (n = 15), undifferentiated spindle cell sarcomas (n = 4), pleomorphic liposarcomas (n = 4), pleomorphic rhabdomyosarcomas (n = 2), and uterine leiomyomas (n = 7) were analyzed for protein expression of PSME1 using immunohistochemistry...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27651889/current-status-and-unanswered-questions-on-the-use-of-denosumab-in-giant-cell-tumor-of-bone
#12
REVIEW
Czar Louie Gaston, Robert J Grimer, Michael Parry, Silvia Stacchiotti, Angelo Paolo Dei Tos, Hans Gelderblom, Stefano Ferrari, Giacomo G Baldi, Robin L Jones, Sant Chawla, Paolo Casali, Axel LeCesne, Jean-Yves Blay, Sander P D Dijkstra, David M Thomas, Piotr Rutkowski
Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension to allow for less morbid surgery. The role of Denosumab for conventional limb GCT of bone is yet to be defined. Further studies are required to determine whether local recurrence rates will be decreased with the adjuvant use of Denosumab along with surgery...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27588167/solitary-fibrous-tumour-presenting-with-a-single-bone-metastasis-report-of-six-cases-and-literature-review
#13
Vittoria Colia, Salvatore Provenzano, Carlo Morosi, Paola Collini, Salvatore Lorenzo Renne, Paolo G Dagrada, Claudia Sangalli, Angelo Paolo Dei Tos, Andrea Marrari, Paolo G Casali, Silvia Stacchiotti
BACKGROUND: Solitary fibrous tumour (SFT) is a rare soft tissue sarcoma with a low metastatic potential. A higher metastatic rate is observed in the high-grade/dedifferentiated variant. The most common expected site of distant spread are the lungs and the liver. Bone involvement is generally viewed as a late stage of disease spread. We report on a retrospective series of SFT patients relapsing with a single distant bone recurrence as first metastatic event, without evidence of other organ involvement...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27525058/primary-intraosseous-meningioma-an-osteosclerotic-bone-tumour-mimicking-malignancy
#14
M Vlychou, Y Inagaki, R Stacey, N A Athanasou
BACKGROUND: Sclerotic tumours of the calvarial bones are rare and may be due to primary and secondary bone tumours as well as extradural tumours of meningeal origin. CASE PRESENTATION: We report a case of primary intraosseous meningioma (PIM) which arose in the frontal bone of a 63 year old woman who complained of progressive pain and thickening of the right skull. Radiology showed a large osteosclerotic lesion in the right frontal bone. Histology showed an intraosseous lesion containing dense fibrous tissue in which there were scattered cells that expressed epithelial membrane antigen and progesterone receptor...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27482375/dendritic-and-mast-cell-involvement-in-the-inflammatory-response-to-primary-malignant-bone-tumours
#15
Y Inagaki, E Hookway, K A Williams, A B Hassan, U Oppermann, Y Tanaka, E Soilleux, N A Athanasou
BACKGROUND: A chronic inflammatory cell infiltrate is commonly seen in response to primary malignant tumours of bone. This is known to contain tumour-associated macrophages (TAMs) and lymphocytes; dendritic cells (DCs) and mast cells (MCs) have also been identified but whether these and other inflammatory cells are seen commonly in specific types of bone sarcoma is uncertain. METHODS: In this study we determined the nature of the inflammatory cell infiltrate in 56 primary bone sarcomas...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27437097/predictors-of-survival-in-patients-with-sarcoma-admitted-to-the-intensive-care-unit
#16
Rohan Gupta, Neda Heshami, Chouhan Jay, Naveen Ramesh, Juhee Song, Xiudong Lei, Erfe Jean Rose, Kristen Carter, Dejka M Araujo, Robert S Benjamin, Shreyaskumar Patel, Joseph L Nates, Vinod Ravi
BACKGROUND: Advances in treatment of sarcoma patients has prolonged survival but has led to increased disease- or treatment-related complications resulting in greater number of admissions to the intensive care unit (ICU). Survival and long-term outcome information about such critically ill patients with sarcoma is unknown. METHODS: The primary objective of the study was to determine the ICU and post-ICU survival rates of critically ill sarcoma patients. Secondary objectives included determining the modifiable and non-modifiable predictors of poor survival...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27403280/patterns-of-care-for-patients-with-advanced-soft-tissue-sarcoma-experience-from-australian-sarcoma-services
#17
Susie Bae, Philip Crowe, Raghu Gowda, Warren Joubert, Richard Carey-Smith, Paul Stalley, Jayesh Desai
BACKGROUND: There is a paucity of data on the current management of patients with advanced soft tissue sarcoma (STS) in the Australian health care setting. This study utilised the Australian sarcoma database to evaluate the patterns of care delivered to patients with advanced STS at Australian sarcoma services. METHODS: Prospectively collected data from six sarcoma centres in Australia were sourced to identify patients diagnosed with advanced STS between 1 January 2010 and 31 December 2012...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27358721/phosphorylated-insulin-growth-factor-i-receptor-p-igf1r-and-metalloproteinase-3-mmp3-expression-in-advanced-gastrointestinal-stromal-tumors-gist-a-geis-19-study
#18
Joan Maurel, Antonio López-Pousa, Silvia Calabuig, Silvia Bagué, Xavier Garcia Del Muro, Xavier Sanjuan, Jordi Rubió-Casadevall, Miriam Cuatrecasas, Javier Martinez-Trufero, Carlos Horndler, Joaquin Fra, Claudia Valverde, Andrés Redondo, Andrés Poveda, Isabel Sevilla, Nuria Lainez, Michele Rubini, Xabier García-Albéniz, Javier Martín-Broto, Enrique de Alava
BACKGROUND: Most GISTs have mutations in KIT or PDGFRA. Patients with advanced GIST with KIT exon 9, PDGFRA mutation or WT for KIT and PDGFRA have a worse progression-free survival (PFS) compared to patients with KIT exon 11 mutated tumors. We evaluated the immunohistochemical (IHC) expression of p-IGF1R (Y1316) and MMP3 as predictors of PFS or overall survival (OS). METHODS: Ninety-two advanced GIST patients included in GEIS-16 study with KIT and PDGFRA mutational information were examined for p-IGF1R (Y1316) and MMP3 expression in a tissue micro-array...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27315524/the-encca-wp7-eurosarc-eec-provabes-euramos-3rd-european-bone-sarcoma-networking-meeting-joint-workshop-of-eu-bone-sarcoma-translational-research-networks-vienna-austria-september-24-25-2015-workshop-report
#19
Leo Kager, Jeremy Whelan, Uta Dirksen, Bass Hassan, Jakob Anninga, Lindsey Bennister, Judith V M G Bovée, Bernadette Brennan, Javier M Broto, Laurence Brugières, Anne-Marie Cleton-Jansen, Christopher Copland, Aurélie Dutour, Franca Fagioli, Stefano Ferrari, Marta Fiocco, Emmy Fleuren, Nathalie Gaspar, Hans Gelderblom, Craig Gerrand, Joachim Gerß, Ornella Gonzato, Winette van der Graaf, Stefanie Hecker-Nolting, David Herrero-Martín, Stephanie Klco-Brosius, Heinrich Kovar, Ruth Ladenstein, Carlo Lancia, Marie-Cecile LeDeley, Martin G McCabe, Markus Metzler, Ola Myklebost, Michaela Nathrath, Piero Picci, Jenny Potratz, Françoise Redini, Günther H S Richter, Denise Reinke, Piotr Rutkowski, Katia Scotlandi, Sandra Strauss, David Thomas, Oscar M Tirado, Franck Tirode, Gilles Vassal, Stefan S Bielack
This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations...
2016: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/27274393/targeted-antiangiogenic-agents-in-combination-with-cytotoxic-chemotherapy-in-preclinical-and-clinical-studies-in-sarcoma
#20
REVIEW
Kieuhoa T Vo, Katherine K Matthay, Steven G DuBois
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. However, when used as monotherapy in the clinical setting, these targeted antiangiogenic agents have only provided modest survival benefits in some sarcoma subtypes, and have not been efficacious in others. Preclinical and early clinical data suggest that the addition of conventional chemotherapy to antiangiogenic agents may lead to more effective therapies for patients with these tumors...
2016: Clinical Sarcoma Research
journal
journal
43933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"